64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer.
Description:
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals (Clarity Clinical)clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
Government Study Link:
NCT05407311 - Click here to see study onClinicalTrials.gov
- • Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy
- • Negative or equivocal findings for PC
- • Adequate liver function
- • Estimated Glomerular Filtration Rate of 30 mL/min or higher.
- • Suspected recurrence of prostate cancer (PC) based on rising Prostate specific antigen (PSA) after definitive therapy
- •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
- • Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
17607 Gold Plaza, Omaha, Nebraska 68130, United States
Myrtle Beach, South Carolina, United States
Los Angeles, California 90048, United States
Miami, Florida 33165, United States
St. Louis, Missouri 63104, United States
Stanford, California 94305, United States
San Antonio, Texas 78229, United States
Grand Rapids, Michigan 49503, United States
